Loading...
XSHG
603233
Market cap2.96bUSD
Jul 10, Last price  
17.65CNY
1D
0.00%
1Q
-0.62%
IPO
21.50%
Name

DaShenLin Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHG:603233 chart
P/E
16.27
P/S
0.73
EPS
1.08
Div Yield, %
3.68%
Shrs. gr., 5y
0.19%
Rev. gr., 5y
13.53%
Revenues
27.50b
+3.80%
3,252,460,2263,706,656,0744,545,011,0065,265,481,8596,273,722,0227,421,196,9028,859,273,70711,141,165,08214,582,865,28216,759,335,26421,248,086,69224,531,390,15226,496,547,00027,502,188,411
Net income
1.24b
+35.04%
149,183,214197,382,183265,501,558395,434,061430,188,675474,960,965531,633,901702,661,9651,062,181,109791,230,9861,035,723,8371,166,498,187914,754,9521,235,246,214
CFO
5.35b
+72.24%
289,310,273288,219,956448,578,297468,587,221495,601,186640,388,127873,639,8441,707,770,7071,953,915,8281,554,994,8633,756,573,4353,173,848,3323,106,300,9785,350,188,615
Dividend
Nov 06, 20250.34 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1999, DaShenLin Pharmaceutical Group Co., Ltd. is a Chinese company based in Guangzhou. It operates across the pharmaceutical supply chain, engaging in the production, distribution, and direct sale of medicinal products throughout the country.
IPO date
Jul 31, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT